Can a new drug make CAR-T therapy safer for lymphoma patients?

NCT ID NCT06550141

First seen Nov 14, 2025 · Last updated Jun 06, 2026 · Updated 33 times

Summary

This study tests whether the drug emapalumab can prevent severe inflammatory side effects (cytokine release syndrome) caused by CAR-T cell therapy. About 28 adults with relapsed or refractory large B-cell lymphoma will receive emapalumab alongside standard CAR-T treatment. The goal is to reduce dangerous immune reactions while still effectively fighting the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.